本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 悦康药业集团股份有限公司（以下简称"公司"或"悦康药业"）控股股东 阜阳京悦永顺信息咨询有限公司（以下简称"京悦永顺"）持有公司股份 180,240,120 股，占公司总股本的比例为 40.05%。截至本公告披露日，本次京悦 永顺持有的本公司 26,500,000 股无限售流通股股票将被司法拍卖。 目前拍卖事项尚在公示阶段，后续可能涉及竞拍、缴款、法院执行法定 程序、股权变更过户等环节，存在一定的不确定性。公司将根据最终结果，依法 履行相应的信息披露义务。 拍卖成交后，买受人后续减持股票需符合《上市公司股东减持股份管理 暂行办法》及《上海证券交易所上市公司自律监管指引第 15 号——股东及董事、 高级管理人员减持股份（2025 年 3 月修订）》等相关规定。同时买受人还需遵守 中国证监会、上海证券交易所等关于上市公司信息披露的相关规定，依法履行信 息披露义务。股票后续能否立即在二级市场进行交易，具体的情况应以监管部门 的认定为准。 京悦永顺持有的部分本公司股份 ...

证券代码：688658 证券简称：悦康药业 公告编号：2025-020 悦康药业集团股份有限公司 关于控股股东部分股份被冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、公司股东股份被冻结的具体情况 股东 名称 是否为控 股股东及 其一致行 动人 冻结股份数 量 占其 所持 股份 比例 占公 司总 股本 比例 冻结股 份是否 为限售 股 冻结起始日 冻结到期日 冻结申请人 冻结 原因 京悦 永顺 是 13,130,000 7.28% 2.92% 否 2025 年 1 月 20 日 2028 年 1 月 19 日 宁波惟精昫竔 股权投资合伙 企业（有限合 伙）、宁波焓湜 枫德股权投资 合伙企业（有限 合伙） 财产 保全 是 2,066,002 1.15% 0.46% 否 2025 年 1 月 27 日 2028 年 1 月 26 日 合计 - 15,196,002 8.43% 3.38% - - - - - 司法冻结，具体情况如下： 悦康药业集团股份有限公司（以下简称"公司"）控股股东阜阳京悦永 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The Chinese traditional medicine sector is expected to experience a relative recovery in 2025, with opportunities in key lines and individual stocks [4][12] - The overall market demand is gradually recovering due to the end of the pandemic and the impact of influenza, leading to a high base and inventory digestion pressure in 2024 [4][12] - The State Council's March 2025 document supports the quality improvement of traditional Chinese medicine, which is expected to stimulate innovation and commercialization of high-quality products [5][13] Summary by Sections Industry Trends - In April 2025, the pharmaceutical and biotechnology sector rose by 1.16%, outperforming the CSI 300 index by 0.77 percentage points [6][15] - The medical research outsourcing sector saw the largest increase of 6.34%, while the vaccine sector experienced the largest decline of 3.78% [20][21] Investment Opportunities - Four main investment lines are identified: 1. Innovative R&D-focused companies with strong capabilities, benefiting from accelerated approvals and optimized procurement, recommended stocks include Fangsheng Pharmaceutical, Yuyuan Pharmaceutical, Tianshili, and Yiling Pharmaceutical [5][14] 2. State-owned enterprises undergoing operational efficiency improvements, recommended stocks include Dong'e Ejiao, Jiangzhong Pharmaceutical, and Kunming Pharmaceutical [5][14] 3. Companies with strong brand power and relatively scarce products, recommended stocks include Zoli Pharmaceutical and Lingrui Pharmaceutical [5][14] 4. Companies experiencing turnaround and valuation recovery, recommended stock includes Jichuan Pharmaceutical [5][14] Market Performance - The traditional Chinese medicine sector has faced pressure since the pandemic, but the situation is expected to improve in 2025 as macro disturbances ease [4][12] - The price index of traditional Chinese medicine materials has been declining since mid-July 2024, which is expected to alleviate the gross margin pressure on companies in 2025 [5][12]

Market Overview - The A-share market indices continued to rise, achieving a five-day consecutive increase, with a total trading volume of 1.31 trillion yuan, a decrease of 78 billion yuan from the previous trading day [1] - The Hainan sector experienced significant growth, while a few sectors such as shipping ports and the茅指数 saw declines [1] Stock Performance - A total of 103 stocks hit the daily limit, with 13 stocks achieving consecutive limit-ups, and 31 stocks failed to close at the limit, resulting in a limit-up rate of 77% (excluding ST and delisted stocks) [3] - Notable stocks included: - Guofang Group achieved a 7-day limit-up, driven by retail and brokerage investments [4] - Zhongqi New Material saw a 10.01% increase, marking its 9th day with 7 limit-ups, influenced by semiconductor equipment [4] - Zhongyuan Home achieved a limit-up, marking its 5th consecutive limit-up, supported by the sofa and e-commerce sectors [4] Institutional Trading - The top three net buying stocks on the Dragon and Tiger list were Hunan Gold, Tianhe Magnetic Materials, and Yuekang Pharmaceutical, with net purchases of 179 million yuan, 157 million yuan, and 106 million yuan, respectively [6] - The top three net selling stocks were Baolingbao, Hongbaoli, and Ouyagu, with net sales of 64.35 million yuan, 54.92 million yuan, and 46.72 million yuan, respectively [6] Sector Highlights - Hunan Gold's stock price surged due to rising gold prices, with spot gold breaking historical highs at $3,245.45 per ounce, and forecasts from Goldman Sachs and UBS predicting further increases [7] - Yuekang Pharmaceutical reported a 42.2 million yuan R&D investment in 2024, accounting for 11.16% of its revenue, reflecting a 0.78 percentage point increase year-on-year [12] - Baolingbao's stock experienced abnormal fluctuations, with a cumulative increase of over 20% in three consecutive trading days, while the company maintains a diverse product range in functional sugars [13] Notable Stock Movements - Kexing Pharmaceutical saw a significant increase of 16.83%, with a trading volume of 288 million yuan and a net institutional purchase of 89.31 million yuan [16] - Ha Sanlian's stock rose by 3.01%, with a trading volume of 787 million yuan and a net institutional purchase of 49.39 million yuan [16] - Qingdao Jinwang's stock increased by 5.41%, with a trading volume of 2.6 billion yuan and a net institutional purchase of 44.02 million yuan [16]

截至2025年4月14日 14:12，上证科创板综合指数(000680)上涨0.61%，成分股悦康药业(688658)上涨 19.91%，科兴制药(688136)上涨16.90%，华丰科技(688629)上涨11.72%，路德环境(688156)上涨8.36%， 南亚新材(688519)上涨8.04%。 数据显示，截至2025年3月31日，上证科创板综合指数(000680)前十大权重股分别为海光信息(688041)、 寒武纪(688256)、中芯国际(688981)、金山办公(688111)、中微公司(688012)、传音控股(688036)、联影 医疗(688271)、百利天恒(688506)、澜起科技(688008)、晶科能源(688223)，前十大权重股合计占比 22.34%。 科创综指ETF鹏华(589680)，场外联接A：023757；联接C：023758。 以上内容与数据，与界面有连云频道立场无关，不构成投资建议。据此操作，风险自担。 申万宏源证券指出，AI产业链持续突破——国产算力突围×物理智能革命×机器人量产元年，市场每次 回调都是筹码再沉淀。后续AI产业链催化节点或集中在5-6月，届时阿里、 ...

Core Viewpoint - The article discusses the recent performance of the STAR Market Composite Index and highlights the impact of U.S.-China trade policies on the pharmaceutical sector, suggesting potential investment opportunities in innovation, overseas markets, equipment upgrades, and consumer recovery [3][4]. Group 1: Market Performance - As of April 14, 2025, the STAR Market Composite Index rose by 1.13%, with notable increases in stocks such as Yuyuan Pharmaceutical (up 19.99%) and Kexing Pharmaceutical (up 17.23%) [3]. - The STAR Market ETF (Hua Xia) also saw a rise of 1.19%, marking its fifth consecutive increase, with a latest price of 0.94 yuan [3]. - The trading volume for the STAR Market ETF was active, with a turnover rate of 23.24% and a transaction value of 197 million yuan [3]. Group 2: Trade Policy Impact - Following the U.S. government's announcement of a 34% tariff on Chinese goods on April 2, 2025, both countries adjusted their bilateral trade tariffs to 125% as of April 11, 2025 [3]. - The frequent adjustments in tariff policies are expected to disrupt U.S.-China pharmaceutical trade, but companies primarily exporting to markets outside the U.S. may be less affected [3]. - The increased tariffs on U.S. goods could accelerate the import substitution process for high-market-share biopharmaceutical products in China [3]. Group 3: Investment Themes - The report suggests focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [4]. - The "innovation" theme emphasizes investing in globally competitive innovative drugs and promising categories with significant market potential [4]. - The "overseas expansion" theme indicates that there are long-term opportunities in overseas markets [4]. - The "equipment upgrades" theme anticipates increased support for medical equipment updates from central and local government financing [4]. - The "consumer recovery" theme highlights potential rebounds in sectors like ophthalmology, dentistry, and medical aesthetics due to consumer stimulus policies [4]. Group 4: ETF Performance and Metrics - The STAR Market ETF (Hua Xia) has reached a new high in scale at 839 million yuan and a new high in shares at 908 million [4]. - Recent net inflows into the ETF totaled approximately 22.08 million yuan, with a total of 57.84 million yuan net inflow over the past five trading days [4]. - The ETF's management fee is 0.15%, and the custody fee is 0.05%, which are among the lowest in comparable funds [5]. - The tracking error for the ETF over the past month is 0.010%, indicating high tracking precision compared to similar funds [5]. Group 5: Valuation Insights - The latest price-to-earnings ratio (PE-TTM) for the STAR Market Composite Index is 129.12, which is at a historical low, being in the 19.67th percentile over the past year [6]. - The top ten weighted stocks in the STAR Market Composite Index account for 22.34% of the index, with companies like Haiguang Information and Cambricon Technologies among the leaders [6].

暗盘资金正涌入这些股票，点击速看>>> 化学制药板块走高，一品红（300723）、悦康药业涨超10%，哈三联（002900）、奥赛康（002755）、 益方生物、海创药业、盟科药业等跟涨。 ...

中国北京市朝阳区北辰东路八号 北辰汇宾大厦 A 座六层 邮编：100101 F6/A，North Star HuiBin Plaza, No.8 BeiChen East Road, ChaoYang District, BeiJing 100101 China 北京天驰君泰律师事务所 关于悦康药业集团股份有限公司 2024 年年度股东会 的 法律意见书 北京 上海 广州 深圳 天津 长春 南京 郑州 成都 福州 Beijing, Shanghai, Guangzhou, Shenzhen, Tianjin, Changchun, Nanjing, Zhengzhou, Chengdu, Fuzhou, 北京天驰君泰律师事务所 关于悦康药业集团股份有限公司 2024 年年度股东会的法律意见书 致：悦康药业集团股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》等相关法律、行政法规，以及中国证券监督管理委员会发布 的《上市公司股东会规则》（以下简称"《股东会规则》"）等规范性文件以 及《悦康药业集团股份有限公司章程》（以下简称"《公司章程》"）的规 定，北京天驰君泰律 ...

证券代码：688658 证券简称：悦康药业 公告编号：2025-019 悦康药业集团股份有限公司 2024 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 9 日 （二） 股东大会召开的地点：北京市北京经济技术开发区科创七街 11 号悦康创 新药物国际化产业园一楼会议室。 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 141 | | --- | --- | | 普通股股东人数 | 141 | | 2、出席会议的股东所持有的表决权数量 | 236,880,862 | | 普通股股东所持有表决权数量 | 236,880,862 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 53.2938 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） ...

Core Viewpoint - The company is celebrating its 40th anniversary in the pharmaceutical industry, marking significant achievements in both generic and innovative drug development, with a clear focus on biopharmaceuticals and internationalization as key strategic directions [2][4][8]. Group 1: Company History and Development - The company was founded in 2001 by Yu Weishi, who aimed to provide affordable and high-quality medicines during a time of rapid growth in the Chinese pharmaceutical market [3]. - Initially focused on generic drug production, the company achieved significant milestones with products like Omeprazole enteric-coated capsules and Ginkgo biloba extract injection, with several products generating annual sales exceeding 1 billion or even 10 billion [3][4]. - By 2012, the company began integrating innovation into its strategy, launching its first Class 1 new drug project and later developing the first domestically produced anti-ED drug [4][5]. Group 2: Research and Development Strategy - The company has established a robust R&D team of over 500 members, collaborating with prestigious institutions to accelerate the translation of research into practical applications [5][6]. - Current R&D strategies focus on innovative drugs targeting cardiovascular diseases, cancer, and infectious diseases, while also developing high-end generic drugs with technical barriers [6][7]. - As of the end of 2024, the company has 42 ongoing research projects, including 21 innovative drugs and 21 generic drugs [4][6]. Group 3: Innovative Drug Pipeline - Several innovative drugs are in the application stage for market approval, including mRNA vaccines and nucleic acid drugs, with significant advancements in clinical trials [7][9]. - The company is actively pursuing breakthroughs in biopharmaceuticals, with a focus on nucleic acid and gene therapy, and aims to have multiple projects entering the application or clinical registration phases annually [7][9]. Group 4: Technological Advancements - The company has invested heavily in new technologies, with R&D expenditures reaching 422 million yuan, accounting for 11.16% of revenue, and has developed eleven major technology platforms [9][10]. - Innovations include breakthroughs in mRNA vaccine technology and AI integration in drug development processes, enhancing efficiency and effectiveness [10][12]. - A strategic partnership with Huawei has been established to advance digital transformation within the pharmaceutical industry [11].